SpinaFX Medical Inc., a Canada-based minimally invasive image-guided therapy start-up, announced on Friday that it has named John Soloninka as its new chief operating officer.
Soloninka has served as a healthtech entrepreneur and ex IBM and Price Waterhouse healthcare system strategist. He has held the position of a CEO and co-founded a USD28m public/private venture debt fund, overseeing a syndicated CAD86M investment in 36 early-stage Healthtech companies including Synaptive Medical, CONAVI, SPARTAN, and Profound Medical. He also co-founded an AI-based oncology management company, ultimately acquired by Varian Medical Systems, and co-founded and headed product development and operations for a cloud-based medical imaging company sold to Merge Technologies of Milwaukee, which was ultimately purchased by IBM. He has served in the research and commercialisation advisory posts with the Rotman Research Institute and the Ontario Brain Institute, and as an expert witness to Canada's Standing Parliamentary Committee on Healthcare.
Soloninka holds a BSc in Engineering Physics from Queen's University and an MBA with Distinction from the Imperial College Business School, London UK.
Scancell initiates SCOPE trial's iSCIB1+ cohort
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Poseida Therapeutics names new chief medical officer
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates
BioVaxys Technology announces non-brokered private placement
Senhwa Biosciences doses first subject in phase II study of Silmitasertib
Antennova completes first dosing cohort in Phase one study of ATN-031
M8 Pharmaceuticals collaborates with SERB Pharmaceuticals
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib
Phanes Therapeutics receives FDA Fast Track designation for PT886